Samsung

St. Louis-based C2N said it will use the funds to scale its clinical laboratory services and Alzheimer's testing capabilities.

During the company's third quarter earnings call, CEO Mark Casper highlighted a number of recent clinical and diagnostic product launches and initiatives.